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S T R U C T U R A L  B I O L O G Y
Synthetic self-assembling ADDomer platform for highly 
efficient vaccination by genetically encoded 
multiepitope display
Charles Vragniau1*, Joshua C. Bufton2*, Frédéric Garzoni3, Emilie Stermann1, Fruzsina Rabi2, 
Céline Terrat4, Mélanie Guidetti5, Véronique Josserand5, Matt Williams6, Christopher J. Woods6, 
Gerardo Viedma7, Phil Bates7, Bernard Verrier4, Laurence Chaperot8, Christiane Schaffitzel2†, 
Imre Berger2,9†, Pascal Fender1†
Self-assembling virus-like particles represent highly attractive tools for developing next-generation vaccines and 
protein therapeutics. We created ADDomer, an adenovirus-derived multimeric protein-based self-assembling 
nanoparticle scaffold engineered to facilitate plug-and-play display of multiple immunogenic epitopes from 
pathogens. We used cryo–electron microscopy at near-atomic resolution and implemented novel, cost-effective, 
high-performance cloud computing to reveal architectural features in unprecedented detail. We analyzed ADDomer 
interaction with components of the immune system and developed a promising first-in-kind ADDomer-based 
vaccine candidate to combat emerging Chikungunya infectious disease, exemplifying the potential of our approach.
INTRODUCTION
Self-assembling protein-based nanoparticles are highly attractive 
tools for a broad range of biomedical applications, including vaccine 
development and cancer therapy (1–4). Present in all kingdoms of 
life, they form supramolecular architectures with unique properties 
(4), including spontaneous self-organization from simple precursor 
protomers amenable to engineering. Moreover, the particle size is 
generally in the range of pathogens, notably viruses, which the immune 
system has evolved to strongly react against (5, 6). Protein-based 
nanoparticles often adopt quasi-spherical shapes encapsulating a 
central cavity that can carry cargo, rendering them suitable to deliver 
drugs (3). Virus-like particles (VLPs) are made of many copies of 
identical building blocks resulting in highly repetitive surfaces, providing 
opportunities to display pathogen-derived epitopes. These are often 
oligopeptide sequences, on their own generally not immunogenic 
enough to elicit a strong immune response resulting in protection 
(5, 6). However, if coupled to self-assembling protomers forming 
the VLP, then peptide epitopes can reach very high densities on the 
VLP, potentially able to trigger B cell receptor clustering and cross- 
presentation for facilitation of a strong immune response (5, 7). Notably, 
VLPs can act as self-adjuvants, alleviating the need to supplement 
vaccine formulations with additional adjuvanting reagents that can 
have undesired side effects (8).
VLPs are intensely researched toward new and better vaccines and 
therapeutics against acute and chronic diseases (2, 3, 9–11). An ideal 
VLP-based vaccine would be safe, free of nucleic acid contaminants, 
amenable to engineering, well produced recombinantly, easy to purify, 
available in large amounts, self-adjuvanting, and capable of eliciting 
a strong immune response to pathogen-derived antigens presented 
in a native conformation at high density on the particle surface. A major 
aspect is thermotolerance—many vaccines today require refrigeration, 
rendering storage and deployment dependent on a functioning cold 
chain, posing problems in remote or less affluent regions (12). Thus, 
thermostability would be a highly advantageous asset for any VLP vaccine.
Human adenoviruses are among the most widely used vectors in 
gene therapy (13). The icosahedral adenovirus capsid comprises 
distinct proteins arranged in hexons, pentons, and fiber extrusions. 
The penton-forming protomer of certain adenovirus serotypes can 
self-assemble into a symmetric, hollow dodecahedron adopted by 
12 pentons comprising altogether 60 protomers (14), effectively 
representing a proteinaceous, nonenveloped VLP. We showed pre-
viously that human adenovirus serotype 3 (Ad3) dodecahedron can 
be produced in baculovirus-infected insect cells (15) and can retain 
the adenovirus-like ability to penetrate epithelial cells (16). We 
studied the structure and mechanism of the Ad3-derived dodecahedron, 
investigating its potential as a delivery system for DNA, proteins, 
and chemical compounds (17–19). Encouraged by these promising 
proof-of-concept results, we set out here to create a synthetic, engineered 
Ad3-derived stable dodecahedron-forming protomer for highly 
efficient multiepitope display and delivery toward a next-generation 
ADDomer VLP platform for vaccines and protein therapeutics.
RESULTS
ADDomer multiepitope display and delivery platform
Comparison of primary sequences of penton-forming protomers 
from many adenovirus serotypes revealed particularly two regions 
of high variability in length and sequence, called variable loop (VL) 
1Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CNRS, CEA, 71 
Avenue des Martyrs, 38042 Grenoble, France. 2Bristol Research Centre for Synthetic 
Biology BrisSynBio, School of Biochemistry, University of Bristol, 1 Tankard’s Close, 
Bristol BS8 1TD, UK. 3Imophoron Ltd., Unit DX, St. Philips Central, Albert Road, Bristol 
BS2 OXJ, UK. 4Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique (LBTI), 
UMR 5305, Université Lyon 1, CNRS, Institut de Biologie et Chimie des Protéines 
(IBCP), Lyon, France. 5Cancer Target and Experimental Therapeutics, Institute for 
Advanced Biosciences, INSERM U1209, CNRS UMR5309, Univesité Grenoble Alpes, 
38700 Grenoble, France. 6Advanced Computing Research Centre, University of Bristol, 
31 Great George Street, Bristol BS1 5QD, UK. 7Oracle Cloud Development Centre, Tower 
Wharf, Cheese Lane, Bristol BS2 2JJ, UK. 8Immunobiology and Immunotherapy in 
Chronic Diseases, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, 
Université Grenoble Alpes, Etablissement Français du Sang-Rhone-Alpes, 38700 
Grenoble, France. 9Max Planck-Bristol Centre for Minimal Biology, Cantock’s Close, 
Bristol BS8 1TS, UK.
*These authors contributed equally to this work.
†Corresponding author. Email: pascal.fender@ibs.fr (P.F.); imre.berger@bristol.ac.uk (I.B.); 
cb14941@bristol.ac.uk (C.S.)
Copyright © 2019 
The Authors, some 
rights reserved; 
exclusive licensee 
American Association 
for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
NonCommercial 
License 4.0 (CC BY-NC).
 o
n
 Septem
ber 26, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Vragniau et al., Sci. Adv. 2019; 5 : eaaw2853     25 September 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 8
and arginine-glycine-aspartic acid (RGD) loop. For instance, VL 
comprises 20 amino acids in Ad3 while only 9 amino acids in Ad41. 
RGD loop plasticity is even more pronounced in Ad12, spanning 11 
residues, in contrast to 74 residues in Ad2. The VL has been shown 
previously to accommodate an influenza-derived immunogenic 
eptitope (20). The RGD loop contains a conserved tripeptide motif 
(-RGD-) mediating integrin-based internalization into target cells (21). 
We reasoned that these regions, VL and RGD loop, given their 
polymorphism, would be ideally suited to accommodate one or several 
antigenic epitopes each. Therefore, we redesigned the protomer- 
encoding gene adopting a “BioBrick” format (22) to facilitate multiple 
epitope insertions. We inspected the crystal structure of Ad3 do-
decahedron (17) and identified suitable loci adjacent to secondary 
structure motifs flanking the loops. The RGD loop in wild-type Ad3 
is considerably more extended than the VL. As the tripeptide is im-
portant for cell internalization, we decided to split the RGD loop 
into two sections before and after the RGD motif, which we kept 
unaltered. We inserted unique restriction sites to create three inde-
pendent loci for epitope display, one in the VL and two in the RGD 
loop to facilitate insertion of synthetic DNAs encoding for antigenic 
epitopes of choice in the resulting plug-and-play multiepitope display 
platform, the ADDomer (Fig. 1A and figs. S1 and S2). We expressed 
ADDomer using MultiBac, the baculovirus/insect cell system we 
developed for complex protein biologics (23), resulting in highly 
purified ADDomer (fig. S1) with excellent culture yields (50 mg from a 
50-ml culture) and negligible nucleic acid or endotoxin contamination.
ADDomer structure and mechanism
Unlocking ADDomer to future structure-based design, we determined 
its molecular architecture by high-resolution cryo–electron micros-
copy (cryo-EM) (Fig. 1, B to H, and figs. S3 and S4). For parts of the 
process, we used public cloud resources, implementing image pro-
cessing and refinement software for this purpose. Our cryo-EM 
structure, at up to 3.2-Å resolution, reveals ADDomer adopting the 
familiar dodecahedron, formed by 12 pentons in a quasi-spherical 
arrangement, with the RGD loop and VL densely decorating the 
particle surface (Fig. 1, B and C, fig. S3, and table S1). Our structure 
shows that the plasticity of the RGD loop and VL, essential for anti-
genic epitope presentation, is maintained in ADDomer (Fig. 1D).
Crystal structures of wild-type Ad3 dodecahedron with and 
without fiber peptide bound exist at lower resolution (3.8 and 4.8 Å, 
respectively) (17). Close inspection of our cryo-EM structure reveals 
notable differences. The fiber-binding cleft adopts a rearranged 
conformation, seemingly in between the geometries observed in the 
crystals of apo- and fiber-bound Ad3 dodecahedron (Fig. 1E) (17). 
The protomer represents a two-domain architecture, with a crown 
region comprising the VL and RGD loop abutting a jellyroll fold 
mediating multimerization (Fig. 1, D and F). In our cryo-EM struc-
ture, we observed additional density in between the crown and jellyroll 
domains, juxtaposed to four sulfur-containing amino acids (M131, 
M138, M458, and C539), consistent with a tetradentate coordination 
by a metal ion, possibly zinc or iron (Fig. 1F). We posit that a structural 
metal ion at this interdomain interface could be important for sta-
bilizing this protein fold.
In the Ad3 dodecahedron crystal, a Ca2+ ion occupied a central 
cavity lined by glutamates (E466) in -helices from different protomers 
(Fig. 1G). No corresponding density is observed by cryo-EM. The 
Ad3 crystallization conditions contained CaCl2, whereas we did not 
supplement Ca2+ during ADDomer purification to occupy this site. 
Consequently, glutamates E466 do not extend into the cavity, but the 
corresponding -helices are slightly shifted in the ADDomer.
A hallmark in the Ad3 crystal structure was strand-swapping be-
tween extended N-terminal regions of neighboring protomers, deemed 
essential to dodecahedron structural integrity (17). Unexpectedly, 
we did not observe this strand-swapping by cryo-EM (Fig. 1H and 
fig. S4C). Rather, in ADDomer, two neighboring protomers engage 
in hydrogen bonds in the vicinity of the twofold axis, extending 
from the S61 side chain to the peptide backbone of E59 and vice versa. 
We can exclude that the differences observed are due to ADDomer 
amino acid additions and substitutions within the VL and RGD 
loop, as they are in the crown domain and thus sterically too distant 
to have a bearing on the N-terminal domain, or the formation of the 
hitherto unobserved metal binding site, respectively.
Strand-swapping and Ca2+ ions would conceivably stabilize the 
dodecahedron. We did not observe either of these features by cryo-EM 
and thus wondered about ramifications for ADDomer stability. Thermal 
shift assays evidenced a melting temperature of 54°C for ADDomer and 
no noticeable melting below 45°C (fig. S5A). We challenged ADDomer 
integrity by storing for weeks at room temperature, freezing and thaw-
ing, and incubating at 45°C. Negative-stain EM revealed uniformly 
stable ADDomer (fig. S5, B to E). Thus, we can conclude that AD-
Domer maintains highly advantageous thermotolerance, begging the 
question what exactly the source of this remarkable stability may be.
ADDomer (30 nm) is within the size range (20 to 200 nm) of 
particles readily drained to lymph nodes, potentiating uptake by 
antigen-presenting cells and cross-presentation (5, 6). We analyzed 
ADDomer uptake by human cells, including monocytes and monocyte- 
derived dendritic cells (MDDCs), confirming efficient internalization 
(Fig. 2, A and B). We next investigated lymph node distribution in 
mice injected with fluorescently labeled ADDomer (Fig. 2, C and D). 
Rapid draining to the right inguinal lymph node was observed irre-
spective of the mode of administration. No signal was found in the 
opposite left inguinal node serving as internal control. Mesenteric 
and axillary nodes evidenced rapid but not lasting signal (Fig. 2D). 
Our results underscore ADDomer capacity to drain rapidly to the 
nearest lymph node and to efficiently penetrate human cells, including 
antigen-presenting lymphocytes.
Engineering ADDomer to combat emerging infectious diseases
Infectious diseases continue to decimate populations worldwide, and 
among our means to combat this threat, vaccination is exceptionally 
powerful. Recent examples that dominated the media are Chikungunya 
and Zika infectious diseases, transmitted by mosquitoes originally 
confined to sub-Saharan Africa but increasingly spreading to the 
Northern Hemisphere. We used our plug-and-play setup to rapidly 
generate ADDomers displaying multiple copies of immunogenic 
epitopes from a range of human and livestock viral pathogens, testing 
the capacity of the insertion loci in the process (fig. S6 and table S2). 
To assess the flexibility of the ADDomer to harbor large multiepitope 
insertions, we combined five immunogenic Gumboro-derived epitopes 
in tandem. Gumboro is caused by infectious bursal disease virus and 
affects poultry, causing significant economic shortfall, particularly 
in developing countries. ADDomer evidenced a remarkable plasticity 
for the insertion of the five tandem Gumboro-derived epitopes in both 
functionalized VL and RGD loop without compromising integrity 
(fig. S6, A and B). Insertion in the VL evidenced a blurring of the 
penton edges, suggesting preferred orientations of the loop structure 
comprising the Gumboro epitopes. Notably, we successfully inserted 
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Fig. 1. Cryo-EM structure of ADDomer. (A) ADDomer design. Three evolutionary nonconserved segments (boxed) in the protomer were engineered by BioBrick design 
into exchangeable cassettes. One cassette (yellow) is located within the VL, while two cassettes, RGD1 (light green) and RGD2 (dark green), are located within the loop 
containing a functional RGD tripeptide sequence. Numbers indicated amino acid boundaries of BioBrick cassettes as well as VL and RGD loop. (B) Left: A 3.5-Å cryo-EM 
map of the ADDomer particle formed by 60 protomers. The rigid core is colored blue, and more flexible regions comprising the loops are colored cyan and green. 
Right: The corresponding atomic model is shown in gray. One penton (center) is highlighted, with individual protomers colored red, orange, green, cyan, and blue, respectively. 
(C) Side view of a penton formed by five protomers. Flexible VL and RGD loop are drawn in dashed lines. (D) Closeup view of the RGD loop and VL in ADDomer. Residues 156 
to 170 in VL and 314 to 366 in RGD loop in the BioBrick format maintain their flexibility, essential for functionalization by epitope insertion. (E) Superimposition of the fiber- 
binding region in the ADDomer cryo-EM structure (cyan) with apo Ad3 [Protein Data Bank (PDB) ID: 4AQQ; marine blue] and fiber peptide–bound Ad3 (PDB ID: 4AR2; magenta) 
crystal coordinates. The fiber peptide (PDB ID: 4AR2) is drawn in a ball-and-stick representation. (F) Individual ADDomer protomer is shown in a side view (left) with a 
putative metal-binding cluster boxed in between the crown (top) and jellyroll fold (bottom) domains. Zoomed-in views of the boxed region (right) depict the atomic 
model in the EM density contoured at two different levels,  = 4 (blue) and  = 10.5 (red). Four juxtaposed sulfurs (yellow spheres) likely coordinate a metal ion. (G) Left: Central 
channel of an ADDomer penton. Right: Ca2+ coordination as seen previously in the Ad3 penton base protein crystal structure (PDB ID: 4AR2) is not observed. The helices 
fencing the central channel are rearranged, resulting in a different conformation of E466. (H) Interface between two pentons (A1 and A2) in the ADDomer (cyan). The 
zoomed-in view depicts the boxed region with the corresponding Ad3 crystal structure (magenta) superimposed. Domain swapping is not observed in the ADDomer. 
Instead, this interface is stabilized by mutual hydrogen bonds between S61 side chains and E59 peptide backbones from neighboring protomers (right).
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a test epitope exceeding 200 amino acid residues in the RGD loop 
(fig. S6B). Together, our data demonstrate full functionality of the 
insertion loci we engineered and convey that long sequences containing 
multiple epitopes can be efficiently displayed at high density on the 
ADDomer.
Notably, sera of most patients suffering from Chikungunya viral 
infection react with a specific linear peptide, E2EP3 (24). This major 
neutralizing epitope is located at the very N terminus of the viral E2 
glycoprotein, comprising the first 18 amino acids (Fig. 3A and table S2). 
We inserted E2EP3 into ADDomer to create a VLP vaccine candidate, 
ADDomer-tevCHIK, with the potential to combat this debilitating 
disease. To recapitulate the exposed conformation of E2EP3 in 
Chikungunya virus, we inserted a site for a highly specific protease 
[tobacco etch virus (TEV) NIa] right in front of the epitope, which, 
upon cleavage, generates a native-like conformation comprising an 
exposed N-terminal serine (Fig. 3A). Processing by TEV resulted in 
quantitative cleavage (Fig. 3B). Negative-stain EM confirmed that, 
impressively, the ADDomer dodecahedron remained intact not-
withstanding multiple (60-fold) polypeptide backbone cuts (Fig. 3C). 
Immunization experiments compellingly validated our approach. 
Uncut ADDomer-tevCHIK did not yield E2EP3-specific immuno-
globulin titers (fig. S7). In contrast, quantitatively cleaved ADDomer- 
tevCHIK exposing native-like E2EP3 elicited very strong specific 
immunoglobulin G (IgG) response concomitant with barely detect-
able IgM (Fig. 3D and figs. S7 and S8), in excellent agreement with 
the immune reaction to Chikungunya viral infection. An unrelated 
nanoparticle scaffold made of polylactic acid harboring the same 
amount of CHIK peptide epitopes did not result in an immune response 
above background in mice, suggesting that the ADDomer scaffold 
itself may have an adjuvanting effect (fig. S7).
DISCUSSION
In summary, we presented here ADDomer, our plug-and-play multi-
epitope display platform for antigenic epitopes from different origins, 
including emerging human viral pathogens or veterinary infectious 
diseases. We determined ADDomer architecture at near-atomic 
resolution by cryo-EM, enabled by a heterogeneous computation 
cluster and created and executed automatically with public cloud 
infrastructure. Our approach presents a novel, fast, and cost-effective 
general mechanism to quickly analyze and process cryo-EM data 
and sets the stage for comprehensive (re)design of the ADDomer 
particle, also to fine-tune self-adjuvanting potential by modulating 
sequence plasticity (25). ADDomer is easy to modify and produce 
in high yields using our recombinant system. It is remarkably thermo-
stable, which could render deployment of ADDomer-based vaccines 
independent of a cold chain, representing a crucial asset. We demon-
strate that ADDomer rapidly drains to lymph nodes and efficiently 
internalizes in immune blood cells. We inserted multiepitope se-
quences exceeding 200 amino acids without compromising ADDomer 
integrity, conveying that even folded domains or entire proteins 
could be displayed. ADDomer can be cleaved multiple times in loops 
without adverse effects, enabling native-like display of epitopes adopt-
ing exposed conformations, compellingly demonstrated here with 
Chikungunya E2EP3. Notably, modification of ADDomer is not 
restricted to the engineered loci. The fiber binding cleft could also 
Fig. 2. ADDomer internalizations. (A) HeLa cells incubated with ADDomer. 4′,6-diamidino-2-phenylindole–stained nuclei are colored blue. ADDomer detected by punctuate- 
specific immunofluorescence is colored red. Scale bar, 20 m. (B) Human monocytes (Mo; left) and MDDCs (right) were incubated with Alexa Fluor 488–labeled ADDomer 
(green). Efficient uptake of ADDomer was observed by in all cell types tested. Scale bars, 20 m. (C) Lymph node biodistribution of Alexa Fluor 680–labeled ADDomer in 
mice. Ex vivo imaging of the main lymph nodes from one representative mouse 5 hours after subcutaneous injection (10 g) in the right leg is depicted in a schematic 
drawing (left). Specific fluorescence signal was quantified (for 100 ms), and intensities (in arbitrary units) are plotted in spectral colors (bottom). (D) Ex vivo quantification 
(for 100 ms) of ADDomer in isolated lymph nodes from a cohort of mice (n = 8) is shown in a bar diagram. Fluorescence was measured at 1 and 5 hours, respectively, after 
intramuscular or subcutaneous injection of Alexa Fluor 680–labeled ADDomer (10 g). Bar color coding is as follows: dark blue, intramuscular at 1 hour; brown, intramus-
cular at 5 hours; light blue, subcutaneous for 1 hour; red, subcutaneous for 5 hours; black, control (noninjected) mice (n = 5). SDs are shown as error bars. Axi, axillary; Bra, 
brachial; Sci, sciatic; Ing fpr, inguinal; Mes, mesenteric lymph nodes; RLU, relative light unit per pixel.
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be used to attach peptides and proteins, tagged with fiber peptide. 
Moreover, the N-terminal extension was shown to react with specific 
binder domains (19), conferring further capacity. Thus, ADDomer 
can accommodate hundreds of epitopes, same or different, providing 
vast opportunity for combinatorial display by a single particle (fig. S9). 
Last, the central cavity within ADDomer could be used to encapsulate 
costimulatory molecules. We anticipate that a wide range of appli-
cations in biomedical research will benefit from this exceptionally 
versatile display platform.
MATERIALS AND METHODS
ADDomer design
We used the penton base protein from human Ad3 (GenBank 
Z29487) as a starting point and implemented a BioBrick format (22) 
to functionalize one locus within the VL and two loci in the RGD 
loop for facile and rapid custom DNA insertion (fig. S1). The inser-
tion loci were flanked by unique restriction sites that were eliminated 
from elsewhere in the Ad3 penton base encoding gene. To preserve 
structural integrity of the penton base protomer, the restriction sites 
were designed in silico to be located outside of and adjacent to known 
secondary structure elements in the penton base protein. The resulting 
gene encoding for ADDomer was synthesized, codon-optimized for 
recombinant expression, and pasted into plasmid pACEBac1 (Geneva 
Biotech SARL, Switzerland) (26) using Bam HI and Hind III restriction 
sites, giving rise to pACEBac-ADDomer. The primary sequence of 
the encoded ADDomer is provided in fig. S2. In this study, pACEBac- 
ADDomer served as the backbone for inserting DNA encoding for 
selected epitopes into the designed insertion loci in the variable and 
RGD loops. Primary sequences of the inserted epitopes in this study 
are listed in table S2.
Expression and purification
pACEBac-ADDomer and epitope-displaying variants were expressed 
using the MultiBac baculovirus expression system we developed 
(fig. S1) (23). Briefly, pACEBac-ADDomer and variant plasmids were 
inserted by Tn7 transposition into an engineered baculoviral genome, 
EMBacY, in DH10EMBacY cells (27). Transfection, baculovirus 
amplification, storage, and protein expression in Hi5 insect cell sus-
pension cultures (50 ml) were performed following established pro-
tocols (27), resulting in exceptional yields (fig. S1). The EMBacY 
baculoviral genome encodes a yellow fluorescent protein (YFP) marker. 
When the YFP signal reached a plateau, cells were harvested by cen-
trifugation, and pellets were flash-frozen in liquid nitrogen and stored 
at −20°C. Pellets were resuspended in hypotonic lysis buffer [0.33× 
phosphate-buffered saline (PBS); 1 ml per 2.5 × 107 cells] supplemented 
by EDTA-free cOmplete protease inhibitor (Roche, Switzerland) and 
lysed by three cycles of freezing and thawing. Lysate was cleared 
from debris by centrifugation (6000g for 30 min), and the cleared 
supernatant was subjected to sucrose gradient (15 to 40%) centrifu-
gation (15). Fractions containing ADDomer (30 to 40% sucrose) were 
pooled and dialyzed against buffer A [10 mM Hepes (pH 7.4) and 
50 mM NaCl]. ADDomer was further purified by ion exchange 
chromatography using a High Q column (Bio-Rad) using buffer A 
and applying a linear salt gradient (50 to 500 mM NaCl). Fractions 
containing highly purified ADDomer (330 to 400 mM NaCl) were 
pooled and stored at ambient temperature or frozen (−80°C). For 
animal studies, ADDomer particles were further purified using 
Detoxi-Gel (Thermo Fisher Scientific) to remove endotoxins, followed 
by dialysis against PBS.
Following purification, absorbance spectroscopy measurement 
showed an OD260nm (optical density at 260 nm)/OD280nm ratio 
below 0.6, evidencing lack of nucleic acid contamination. Before in-
jection into mice, endotoxin levels were quantified using Endosafe 
PTS (Charles River) evidencing 754 EU (endotoxin units)/mg for 
ADDomer-tevCHIK and 247 EU/mg for ADDomer, respectively. 
In our injections, we thus were below 30 EU, the common cutoff 
value for testing adjuvant properties of any recombinant antigen in 
a mouse model.
Thermostability measurements
Highly purified ADDomer sample was stored in PBS at room tem-
perature. Thermal shift experiments were performed at an ADDomer 
concentration of 3 mg/ml in PBS, using a ThermoFluor assay (28). 
ADDomer sample was diluted to 1 mg/ml and aliquoted. Identical 
sample aliquots were stored for several weeks at room temperature, 
frozen at −20°C overnight followed by thawing, and incubated at 45°C 
Fig. 3. ADDomer immunizations. (A) Top: Chikungunya envelope protein E2, 
composed of domains A, B, and C, is shown in a schematic representation. The major 
neutralizing epitope E2EP3 (red) comprises the N terminus of E2 with the amino 
acid sequence NH2-STDKDNFNVYKATRPYLAH. Bottom: This specific configuration 
of E2E3P was mimicked in ADDomer-tevCHIK as depicted by inserting the E2EP3 
sequence (in red), preceded by a TEV protease cleavage site (orange) into the BioBrick 
cassette in VL of the ADDomer protomer. Cleavage by the protease exposes 
E2EP3 in a native-like configuration as shown schematically. (B) SDS–polyacrylamide 
gel electrophoresis section showing purified ADDomer-tevCHIK before and after 
cleavage by TEV protease. Molecular weight marker sizes are marked (left). Appear-
ance of two bands (black triangles) indicates quantitative cleavage. (C) Represent-
ative negative-stain EM images of TEV-cleaved ADDomer-tevCHIK reveals stable 
dodecamers. Scale bar, 30 nm. (D) This TEV-cleaved sample was used in immuniza-
tion experiments in mice (n = 10 per group). Scatter dot plot diagram depicts the 
outcome of the immunization experiments, revealing high individual IgG titers 
specific for Chikungunya E2E3P peptide in enzyme-linked immunosorbent assay 
(ELISA). Short horizontal line segments are geometric mean titers, and error bars 
represent the 95% confidence interval. Significant difference (****P < 0.0001) was 
determined between ADDomer-tevCHICK– and ADDomer-only immunized mice.
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for 1 hour, respectively. Sample integrity was assessed at each inter-
vention by negative-stain EM (fig. S5).
Negative-stain EM
Negative-stain EM was performed with purified ADDomer (0.1 to 
0.5 mg/ml) dialyzed into 25 mM Hepes (pH 7.5), 150 mM NaCl, 
and 2 mM EDTA. Sample was stained with 3% uranyl acetate. Micro-
graphs were recorded using a 200-kV FEI Tecnai T20 microscope 
with an Eagle 4k × 4k charge-coupled device camera.
Cryo-EM and data collection
Five microliters of purified ADDomer (0.1 mg/ml) was applied to 
glow-discharged holey carbon grids (Quantifoil, R 2/2 300 mesh). 
Samples were incubated on the grid for 2 s and blotted for 0.4 s at 
90% relative humidity and 18°C inside a Leica EM GP, before plunge- 
freezing in liquid ethane. Cryo-EM data were collected at 200 kV 
with a FEI Talos Arctica microscope equipped with a Gatan K2 direct 
electron detector and an energy filter using automated acquisition 
software (EPU). A total of 1060 dose-fractionated movies each con-
taining 32 frames (0.25 s per frame) with an accumulated total dose 
of 42 e−/Å2 were recorded at a nominal magnification of ×130,000 
corresponding to a pixel size of 1.06 Å. Images were recorded with 
a defocus range of −0.8 to −3.2 m (table S1).
Image processing
Image processing was performed with the RELION 2.1 software package 
(29). The micrographs were motion-corrected using MotionCorr2 
(30), and contrast transfer function (CTF) information was determined 
using ctffind4.1 (31). Together, 262 micrographs with CTF rings ex-
tending beyond 4.6 Å were selected for further processing. A total of 
3600 particles were boxed using RELION autopicking software. After 
two-dimensional (2D) classification (fig. S3C) and 3D classification 
with imposed icosahedral symmetry, initial 3D autorefinement 
led to a reconstruction of ~4.2-Å resolution. Further rounds of 3D 
classification/refinement were carried out on polished particles before 
using postprocessing for masking and automatic B factor sharpening. 
The resolution of the final map was determined to be 3.5 Å based on 
the Fourier shell correlation (FSC) 0.143 cutoff criterion (fig. S3D) 
(32). Local resolution was calculated using local resolution estimation 
program in RELION (fig. S3E).
Processing and 3D classification of ADDomer were performed 
using public cloud resources provided by the Oracle Cloud Infra-
structure. Using this rather than an institutional cluster allowed a 
faster turnaround time of analysis. Because of the particular nature 
of the computational work carried out by the steps within RELION, 
a heterogeneous cluster was prepared with both central processing 
unit (CPU)– and graphical processing unit (GPU)–focused resources. 
A pipeline of workloads was created, allowing the work best suited 
to each compute type to use just the resources needed and to auto-
matically release compute resources when no longer needed. This 
permitted parts of the workflow to use lower-cost CPU resources 
and to burst to GPU only for those parts that would benefit from 
GPU optimization, reducing overall cost while increasing total data 
throughput. The total cost for running the image processing pipeline 
on the cloud was approximately £200.
Model building and refinement
Homology modeling was performed using I-TASSER (33) using the 
human adenovirus Ad3 structure as template (17). The model was 
adjusted to fit into the map manually using COOT (34) before fur-
ther iterative positional and B factor refinement in real space using 
Phenix Real-Space refinement software (35). Final adjustments were 
carried out in COOT before evaluating the model using MolProbity 
(36). Refinement statistics are summarized in table S1.
Cell culture and differentiation
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum (FCS) (Thermo Fisher 
Scientific) at 37°C under 5% CO2. Monocytes were purified by 
centrifugation on Ficoll (Sigma-Aldrich) for 20 min at 800g, and 
mononucleated cells were subsequently passed through EasySep 
magnetic beads (STEMCELL Technology). Monocyte purity was 
verified by flow-cytometry by means of CD14 labeling. MDDCs 
were generated by cultivating monocytes in RPMI 1640 FCS medium 
supplemented with granulocyte-macrophage colony-stimulating 
factor at 100 ng/ml and interleukin-4 at 25 ng/ml for 6 days. Differ-
entiation to MDDCs was verified by FACS based on CD14/CD209 
labeling.
Imaging
HeLa cells were grown on a glass coverslip and incubated for 1 hour at 
37°C with unlabeled ADDomer at 20 g/ml. Subsequent to methanol 
fixation, rabbit serum raised against human Ad3 penton base protein, 
diluted 1:1000 in PBS, was applied, followed by Cy5-labeled goat 
anti-rabbit antibody (Jackson ImmunoResearch), diluted 1:500 in PBS. 
Nuclei were stained by the DNA dye 4′,6-diamidino-2-phenylindole.
Monocytes and MDDCs from healthy anonymous donors were ob-
tained from the National Blood Service [Etablissement Francais du Sang 
(EFS), La Tronche] after written consent following approval by the 
EFS. ADDomer (1 mg/ml) was labeled with Alexa Flour 488 dye 
(Invitrogen) following the manufacturer’s recommendations. Un-
bound dye was removed by extensive dialysis against PBS overnight. 
About 105 monocytes or MDDCs, respectively, were incubated for 
1 hour at 37°C with 10 g of labeled ADDomer. Cells were applied to 
glass coverslips and analyzed using differential interference contrast and 
green fluorescence channels in an Olympus IX81 inverted microscope.
Biodistribution studies
ADDomer was labeled with Alexa Fluor 680 dye (Invitrogen) fol-
lowing the same procedure as above for Alexa Flour 488 labeling. 
Alexa Flour 680–labeled ADDomer sample was injected in 9-week-old 
female BALB/cJRj mice (Janvier Labs, France). Four control mice 
(no injection) were used for tissue autofluorescence quantifications. 
Mice were anesthetized (isoflurane/air, 4% for induction and 
1.5% thereafter), and injections were performed either subcutaneously 
(n = 8; right flank; 100 l; 0.1 mg/ml) or intramuscularly (n = 8; 
right quadriceps; 12 l; 0.85 mg/ml). Mice were euthanized at either 
1 hour (n = 4 per group) or 5 hours (n = 4 per group) after injection. 
Main lymph nodes (mesenteric, sciatic, axillary, inguinal, and brachial) 
were sampled and imaged using FLUOBEAM700 (Fluoptics, France) 
with 680-nm excitation and LP (Long Pass) 700-nm emission. Fluo-
rescence radiance from each lymph node was quantified in relative 
light units per pixel per 100 ms.
Immune studies
Initial test immunizations
Six-week-old female BALB/c mice were subcutaneously injected, 
and sera were collected and treated as described previously (37). 
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Immunizations were carried out with 10 g each of ADDomer, 
ADDomer-tevCHIK (uncut), or ADDomer-tevCHIK quantitively 
cleaved by TEV protease, respectively. Specific antibodies in sera 
were detected by enzyme-linked immunosorbent assay (ELISA) in 
duplicate using 96-well plates coated with CHIK peptide (0.1 g/ml). 
Horseradish peroxidase (HRP)–conjugated goat anti-mouse IgG 
1030-05 (SouthernBiotech) was used for detection [concentration 
of 0.1 g/ml in PBS with 1% bovine serum albumin (BSA)] for 1 hour 
at 37°C, supplemented with 100 l of tetramethylbenzidine (TMB) 
substrate (Becton Dickinson) per well. Reactions were stopped by 
adding H2SO4 (0.2 N), and OD was measured in a microplate reader 
(Thermo Fisher Scientific) at 450 nm (fig. S7).
ADDomer-tevCHIK immunization experiments
Ten B6D2F1 mice per group received twice (study days 1 and 15) 
subcutaneously 40 g per mouse of ADDomer (group 1) or quanti-
tatively cleaved ADDomer-tevCHIK (group 2). Control mice were 
immunized twice with the buffer diluent. Mice were observed cage-side 
for clinical symptoms. Mice immunized with ADDomer (group 1) 
and ADDomer-tevCHIK (group 2) developed high serum IgG titers 
(<12,800) after the first and second immunization. Mice immunized 
with diluent did not induce ADDomer-specific IgG. IgM and IgG 
titers were <100 in serum samples collected before immunization. 
All mice immunized with ADDomer-tevCHIK sample developed 
CHIK-specific IgG after the first immunization (GMT, 2425; titer 
range, 400 to 6400). After the second immunization, IgG titers sub-
stantially increased (GMT, 19,400; titer range, 6400 to 51,200). Mice 
immunized with ADDomer (empty) and diluent did not develop 
CHIK-specific IgG titers. In contrast, only 1 of 10 mice immunized 
with ADDomer-tevCHIK developed detectable CHIK epitope–specific 
IgM after the first (titer, 1:50) and second (titer, 1:100) immunization. 
No CHIK-specific IgM could be determined in mice immunized with 
ADDomer or diluent.
Blood was collected by the facial vein technique at days 1, 14, and 35. 
Briefly, the mouse was gently and securely restrained in the opera-
tor’s nondominant hand. The hairless freckle on the side of the 
jaw was located and pricked with a sharp lancet held by operator’s 
free hand (sharp end of the lancet points at the far side of the mouse’s 
face, at the base of the far ear, or at the base of the far side of the 
mouth). About four to seven drops of blood were collected in an 
Eppendorf tube, and the mouse was released into its cage. Blood 
samples were centrifuged twice in a bench centrifuge for 5 min at 
10,000g at 4°C, and collected serum was stored below −18°C before 
analyses. An ELISA protocol was developed using streptavidin-coated 
plates and the biotinylated CHIK peptide (table S2) following estab-
lished protocols (Thermo Fisher Scientific). Briefly, streptavidin- 
coated plates were washed three times with 200 l of wash buffer [25 mM 
tris-HCl (pH 7.2), 150 mM NaCl, 0.1% BSA, and 0.05% Tween 20]. 
Next, 100 l of biotinylated CHIK peptide dissolved in dimethyl 
sulfoxide and diluted in PBS to a final concentration of 2.5 g/ml in 
PBS was added to each well. Plates were incubated for 2 hours on a 
plate shaker at room temperature. After extensive washing, twofold 
serially diluted serum samples were added (100 l per well). Plates 
were incubated for 1 hour with occasional shaking at room tempera-
ture. After three additional washing steps, 100 l of goat anti-mouse 
IgM or HRP-conjugated IgG antibody (diluted 1:2000; Sigma-Aldrich), 
respectively, was added to each well, and plates were incubated for 
45 min at room temperature. Plates were again extensively washed 
before adding 100 l of color substrate (TMB) per well, followed by 
shaking. The color reaction was stopped with H2SO4 (0.2 N), and 
OD was measured at 450 nm. To determine serum IgM or IgG ti-
ters, a cutoff value was defined as mean absorption value of negative 
blank samples plus three times the SD.
In vivo experimentation statement
In vivo experiments were carried out in France at the Institute for 
Advanced Biosciences (Grenoble) and the Institute of Biology and 
Chemistry of Proteins (Lyon). These laboratories are certified by 
the French Ministry of Research and Education Superior and regularly 
monitored by the French Departmental Directorate for the Protection 
of Population (approval numbers C 69 123 0303 and C38 516 10001). 
Immunization studies were carried out at the Institute of Virology, 
Biomedical Research Centre, Slovak Academy of Sciences (Bratislava). 
Animal care was in compliance with the standard operation proce-
dures of the Institute of Virology and the European Convention for 
the Protection of Vertebrate Animals used for experimental and other 
scientific purposes (ETS 123) with approval from the Veterinary State 
Administration, Slovak Republic (Statna veterinarna a potravinova 
sprava Slovenskej republiky), and institutional ethical committee. 
All animal experiments were carried out according to the rules in 
force and in the respect of the ethics of the animal experimentation.
Statistics
Statistical significance was determined by calculating SDs following 
standard mathematical formulae (unpaired t test with Welch’s cor-
rection of log-transformed titer values).
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